DCM
CLSD

DAFNA Capital Management’s Clearside Biomedical CLSD Stock Holding History

DAFNA Capital Management’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-333
Closed -$54K – 76
2018
Q1 		$54K Buy
+333
New +$40.6K 0.03% 74

Other funds holding CLSD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
NC
Northpointe Capital Bloomfield Hills, Michigan $258M AUM 1.97% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

DAFNA Capital Management's CLSD Position: Q2 2018 in Review

DAFNA Capital Management sold out of Clearside Biomedical (CLSD) in Q2 2018, closing a stake of 333 shares — an estimated $54K sold.

DAFNA Capital Management first reported a position in CLSD in Q1 2018 and held it in 1 quarter. The position peaked at $54K in Q1 2018. 86 funds tracked by Wall St. Rank hold CLSD as of Q2 2018.

  • DAFNA Capital Management reported no remaining Clearside Biomedical position as of Q2 2018 after selling out during the quarter.
  • DAFNA Capital Management sold 333 Clearside Biomedical shares in Q2 2018, an estimated $54K.
  • DAFNA Capital Management first reported a position in Clearside Biomedical in Q1 2018 and held it in 1 quarter.
  • DAFNA Capital Management's Clearside Biomedical position peaked at $54K in Q1 2018.
  • 86 funds tracked by Wall St. Rank held Clearside Biomedical as of Q2 2018.

Based on DAFNA Capital Management's 13F filing for Q2 2018, filed 13 Aug 2018.